Teishima J, et al. - Experts gauged the prognostic effect of the change in C-reactive protein (CRP) level before and after cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitor. They measured the CRP in patients undergoing molecular targeted therapy for mRCC before and after CN. In patients with mRCC treated with tyrosine kinase inhibitor, the CRP level after CN could be a predictive factor for OS. Patients in the lower CRP, normalized CRP, and nonnormalized CRP groups demonstrated the OS of 28.6, 23.1, and 12.3 months, respectively.